Probiotic Lactobacillus rhamnosus LRa05 for blood sugar in gestational diabetes
Tests the probiotic Lactobacillus rhamnosus LRa05 in pregnant women with gestational diabetes.
Key facts
- Who runs it
- Wecare Probiotics Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes
- Status
- Recruiting
- People taking part
- 80 people, planned
- Started
- 10 Apr 2025
- Planned end
- 10 Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Conventional treatment and Probiotic
- Record updated
- 30 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with gestational diabetes (diabetes that starts in pregnancy). It tests the probiotic Lactobacillus rhamnosus LRa05 on blood sugar and gut bacteria.
- Age
- 18 to 50 years
- Sex
- Pregnant women
- Disease stage
- Gestational diabetes found at 24 weeks of pregnancy by an abnormal sugar drink test (OGTT). Pregnancy with one baby, with no structural or chromosome problems found.
- Earlier treatment
- No probiotic-containing foods (such as yogurt, fermented foods, soybean paste) in the 2 weeks before the study. No recent use of products that work like the study product.
- Biomarker or test result
- OGTT with an 82.5g glucose load: fasting ≥ 5.1 mmol/L (92 mg/dL), 1-hour ≥ 10 mmol/L, or 2-hour ≥ 8.5 mmol/L (one or more).
Main reasons for not taking part
- Long-term diseases such as immune deficiency, high blood pressure, diabetes, kidney or liver disease
- Other hormone diseases, or medicines that affect blood sugar or blood fats
- Severe heart, kidney, liver or gut diseases
- Use of medicines that weaken the immune system
- Allergy to probiotics or study product parts; smoking, drinking alcohol or drug abuse
This trial only enrols pregnant participants. The registry sentence this rests on: 2. Pregnant women aged 18 to 50 years.
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Women diagnosed with gestational diabetes mellitus (GDM) at 24 weeks of gestation; Diagnostic criteria for GDM: Abnormal oral glucose tolerance test (OGTT) with an 82.5g glucose load during the 24th week of pregnancy (defined as meeting one or more of the following plasma glucose thresholds: fasting ≥ 5.1 mmol/L, 1-hour ≥ 10 mmol/L, or 2-hour ≥ 8.5 mmol/L)
- Pregnant women aged 18 to 50 years
- Singleton pregnancy with a fetus confirmed to be structurally and chromosomally normal via ultrasound or other prenatal diagnostic methods
- No history of chronic diseases, including immune deficiency, hypertension, diabetes, kidney disease, or liver disease
- No consumption of probiotic-containing foods (e.g., yogurt, fermented foods, soybean paste) within the two weeks prior to the study
- Willing and able to provide written informed consent
- Capable of complying with the study protocol and follow-up requirements
Who cannot take part
- Those with immunodeficiency diseases or currently using immunosuppressive agents
- Those with unhealthy lifestyle habits, such as smoking, alcohol consumption, or drug abuse
- Those with severe cardiovascular, kidney, or liver diseases
- Those with severe gastrointestinal diseases that may affect the absorption or metabolism of probiotics
- Those with a history of allergy to probiotics or any components of the study products
- Those with other endocrine diseases or currently using medications that affect blood glucose control
- Those currently using other medications that may affect blood glucose control or lipid levels
- Those who have taken items with similar functions to the test product in the short term, which may affect the judgment of the results
- Those who do not consume the test samples as required or do not follow up on time, resulting in uncertain efficacy
- Study participants deemed unsuitable by other researchers
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes. Initially, the study will investigate the effects of LRa05 on improving patients' blood glucose levels and gut microbiota. Additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (BMI). Furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.
The 2 groups in the trial
- Probiotic GroupTreatment being tested
Participants will follow a controlled diet and exercise regimen, while also consuming the probiotic Lactobacillus rhamnosus LRa05 at a dosage of one stick per day (each stick contains 3 grams with 30 billion CFU), continuing until delivery.
Treatment: Conventional treatment and Probiotic
- Placebo GroupNo study treatment, for comparison
Participants will only receive standard treatment (diet control and exercise therapy) until delivery.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessing the Efficacy of Lactobacillus Rhamnosus LRa05 in Improving Blood Glucose and Gut Microbiota in Patients With Gestational Diabetes
- Plain-language title
- Probiotic Lactobacillus rhamnosus LRa05 for blood sugar in gestational diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06901791, who can take part
- Record updated
- 30 March 2025